Evidence-based medicine and clinical fluorodeoxyglucose PET/MRI in oncology

Cancer Imaging

Table 4 Summary of the results of test accuracy in studies comparing combined MRI and FDG-PET/CT to PET/CT alone for the classification of patients with or without tumour recurrence

Study	Population & setting	Reference standard and comparator	Outcome [95 % CI]
			PET/CT		PET/MR
			Sensitivity	Specificity	Sensitivity	Specificity
Xu et al. (2013) [22]	Meta-analysis of 4 studies comparing PET/CT and WB-MRI in the detection metastatic head & neck cancer (n = 511)	Reference standard variable.	82 [69–90] %	97 [94–98] %	89 [86–96] %	98 [97–99] %
Xu et al. (2013) [22]		Combined reading of PET and WB-MRI	82 [69–90] %	97 [94–98] %	89 [86–96] %	98 [97–99] %
Donati et al. (2010) [21]	Hepatic metastases (n = 37, CRC: n = 20)	Histology or follow-up Fused PET/MR	100 [77–100] %	92 [67–99] %	100 [77–100] %	100 [77–100] %
Beiderwellen et al. (2014) [23]	Skeletal metastases (n = 67)	Histology or follow-up	90 [68–98] %	100 [72–100] %	100 [94–100] %	100 [94–100] %
Beiderwellen et al. (2014) [23]	Skeletal metastases (n = 67)	Dedicated PET/MR	90 [68–98] %	100 [72–100] %	100 [94–100] %	100 [94–100] %

ISSN: 1470-7330